Research Progress on Cardiac Tissue Construction of Mesenchymal Stem Cells for Myocardial Infarction.

IF 2.1 4区医学 Q4 CELL & TISSUE ENGINEERING Current stem cell research & therapy Pub Date : 2024-01-01 DOI:10.2174/1574888X18666230823091017

Guo-Dong Yang, Da-Shi Ma, Chun-Ye Ma, Yang Bai

{"title":"Research Progress on Cardiac Tissue Construction of Mesenchymal Stem Cells for Myocardial Infarction.","authors":"Guo-Dong Yang, Da-Shi Ma, Chun-Ye Ma, Yang Bai","doi":"10.2174/1574888X18666230823091017","DOIUrl":null,"url":null,"abstract":"<p><p>Heart failure is still the main complication affecting the prognosis of acute myocardial infarction (AMI), and mesenchymal stem cells (MSCs) are an effective treatment to replace necrotic myocardium and improve cardiac functioning. However, the transplant survival rate of MSCs still presents challenges. In this review, the biological characteristics of MSCs, the progress of mechanism research in the treatment of myocardial infarction, and the advances in improving the transplant survival rate of MSCs in the replacement of necrotic myocardial infarction are systematically described. From a basic to advanced clinical research, MSC transplants have evolved from a pure injection, an exosome injection, the genetic modification of MSCs prior to injection to the cardiac tissue engineering of MSC patch grafting. This study shows that MSCs have wide clinical applications in the treatment of AMI, suggesting improved myocardial tissue creation. A broader clinical application prospect will be explored and developed to improve the survival rate of MSC transplants and myocardial vascularization.</p>","PeriodicalId":10979,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current stem cell research & therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1574888X18666230823091017","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

Heart failure is still the main complication affecting the prognosis of acute myocardial infarction (AMI), and mesenchymal stem cells (MSCs) are an effective treatment to replace necrotic myocardium and improve cardiac functioning. However, the transplant survival rate of MSCs still presents challenges. In this review, the biological characteristics of MSCs, the progress of mechanism research in the treatment of myocardial infarction, and the advances in improving the transplant survival rate of MSCs in the replacement of necrotic myocardial infarction are systematically described. From a basic to advanced clinical research, MSC transplants have evolved from a pure injection, an exosome injection, the genetic modification of MSCs prior to injection to the cardiac tissue engineering of MSC patch grafting. This study shows that MSCs have wide clinical applications in the treatment of AMI, suggesting improved myocardial tissue creation. A broader clinical application prospect will be explored and developed to improve the survival rate of MSC transplants and myocardial vascularization.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

间充质干细胞用于心肌梗死的心脏组织构建研究进展。

心力衰竭仍是影响急性心肌梗死（AMI）预后的主要并发症，而间充质干细胞（MSCs）是替代坏死心肌、改善心脏功能的有效治疗方法。然而，间充质干细胞的移植存活率仍面临挑战。本综述系统阐述了间充质干细胞的生物学特性、治疗心肌梗死的机制研究进展以及提高间充质干细胞替代坏死心肌梗死的移植存活率的进展。从基础研究到高级临床研究，间充质干细胞移植经历了从单纯注射、外泌体注射、注射前对间充质干细胞进行基因修饰到间充质干细胞贴片移植的心脏组织工程。这项研究表明，间充质干细胞在治疗急性心肌梗死方面具有广泛的临床应用前景，它能改善心肌组织的生成。为了提高间充质干细胞移植的存活率和心肌血管化，我们将探索和开发更广阔的临床应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current stem cell research & therapy CELL & TISSUE ENGINEERING-CELL BIOLOGY

CiteScore

4.20

自引率

3.70%

发文量

197

审稿时长

>12 weeks

期刊介绍： Current Stem Cell Research & Therapy publishes high quality frontier reviews, drug clinical trial studies and guest edited issues on all aspects of basic research on stem cells and their uses in clinical therapy. The journal is essential reading for all researchers and clinicians involved in stem cells research.